OMDA

Omada Health, Inc. 10-Q Summary: Quarter Ended September 30, 2025

Business Context and Reporting Period

This filing covers the quarterly period ended September 30, 2025. Omada Health, Inc. (OMDA) is a digital health company providing virtual care programs for cardiometabolic conditions (prediabetes, diabetes, hypertension), musculoskeletal (MSK) conditions, and behavioral health. The company completed its Initial Public Offering (IPO) on June 9, 2025, raising approximately $151.6 million in net proceeds. As of September 30, 2025, the company had 831,000 total members enrolled in its programs.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Net loss per share (basic and diluted) was $(0.06) for Q3 2025 and $(0.61) for the nine months ended September 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 49% year-over-year (YoY) in Q3 and 51% for the nine-month period, driven primarily by a 52% increase in total members.
• Margin Expansion: Gross margin expanded by 3.5 percentage points in Q3 and 5.5 percentage points for the nine months, attributed to Care Team efficiency initiatives and technology adoption.
• Debt Extinguishment: The company fully repaid its MidCap Term Facility and Revolving Facility (approx. $31.4 million principal and accrued interest) on July 31, 2025, using IPO proceeds. This resulted in a $2.1 million loss on debt extinguishment recorded in Q3.
• Interest Income: Interest income surged to $2.0 million in Q3 (from $0.017 million in Q3 2024) due to higher cash balances from the IPO.
• Operating Expenses: Sales and marketing expenses increased 31% YoY in Q3, largely due to higher administrative fees paid to channel partners and increased headcount.

Guidance, Outlook, and Risks

• Liquidity: The company holds $198.6 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
• Seasonality: The business experiences seasonality with higher sales closures in Q2 and Q3 aligning with benefits enrollment, leading to higher enrollments and costs in Q1 and Q2.
• Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2025, due to previously identified material weaknesses in internal control over financial reporting (segregation of duties, insufficient technical personnel, and inadequate formalized processes). Remediation efforts are ongoing.
• Customer Concentration: Revenue is highly concentrated. Two affiliates of The Cigna Group (Partner A and Partner B) accounted for 32% and 34% of Q3 revenue, respectively. The top five partners represented 76% of Q3 revenue.
• Regulatory & Market Risks: Risks include evolving regulations on AI and virtual care, potential FDA scrutiny of software as a medical device, and the impact of GLP-1 therapy adoption on demand for lifestyle programs.

Investor Verification Checklist

• Customer Concentration: Verify the stability of contracts with The Cigna Group affiliates, which represent over 65% of recent revenue.
• Internal Control Remediation: Monitor progress on remediation of material weaknesses in internal controls to ensure future financial reporting reliability.
• Debt Status: Confirm the company remains debt-free post-IPO and assess the impact of the $2.1 million extinguishment loss on future profitability projections.
• Member Engagement: Review metrics on member retention and engagement rates, as revenue recognition is tied to member activity and clinical outcomes.
• Hardware Costs: Assess exposure to tariffs and supply chain disruptions for connected devices (scales, monitors) manufactured internationally, which impact cost of revenue.